Source comparison
Recovery-Specific Dosing: Acute vs Chronic Repair Protocols
Acute injury recovery protocols. Defined as tissue damage occurring within the past 72 hours. Use lower Sermorelin doses (200-350mcg daily) than chronic repair models. The reason is mechanistic: acute inflammation following injury upregulates GHRH receptor den
This comparison does not assign a generated winner or score.
- Acute injury recovery protocols. Defined as tissue damage occurring within the past 72 hours. Use lower Sermorelin doses (200-350mcg daily) than chronic repair models. The reason is mechanistic: acute inflammation following injury upregulates GHRH receptor density in damaged tissue by 40-60% in the first week post-injury, according to research published in the Journal of Cellular Physiology in 2025. Higher receptor availability means lower doses produce the same downstream IGF-1 and collagen synthesis response that would require 500mcg in non-injured tissue. Researchers dosing acute models at 500-600mcg often report paradoxical results. Elevated systemic GH without proportional improvement in localized healing markers. Because supraphysiological pulsing triggers negative feedback that blunts the endogenous repair cascade.
- Chronic repair models. Tendon degeneration, delayed wound healing, age-related muscle atrophy. Operate differently. GHRH receptor density in chronically damaged tissue is often downregulated by 20-35% compared to healthy tissue, requiring higher doses (400-500mcg) to achieve the same receptor occupancy. A 2025 study from Stanford tracked Achilles tendon repair in aging rodent models and found 400mcg daily Sermorelin produced measurable improvements in tensile strength at 8 weeks, while 250mcg showed no significant difference from control. The dose-response curve in chronic models is steeper. Small increases in dose produce disproportionately larger effects until a plateau around 600mcg, after which additional dose adds systemic GH effects without further improving the primary repair outcome.
- Injection timing relative to the injury phase also matters. Administering Sermorelin during the inflammatory phase (first 48-72 hours post-injury) can extend inflammation and delay transition to the proliferative phase. Researchers working with surgical models typically begin dosing 72 hours post-procedure to avoid this. In contrast, chronic repair models show benefit from immediate dosing because there's no discrete injury event to time against. Dose and timing are inseparable variables in recovery research. Changing one without adjusting the other introduces confounding that most statistical models can't fully account for.